Vivalis, sanofi-aventis deal

Vivalis granted Sanofi Pasteur, the vaccines division of sanofi-aventis, exclusive access to its Humalex technology to discover human mAbs to treat and prevent nosocomial infections and other infectious diseases not preventable with vaccines. Sanofi Pasteur will fund research of the mAbs and have exclusive, worldwide rights to develop and commercialize resulting drug candidates. Vivalis will receive €3 million ($3.6 million) up front and is also eligible for up to €35 million ($41.8 million) in milestones for each indication, plus royalties. ...